Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants
- 12 March 2024
- journal article
- research article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 264 (Pt 2) , 130820
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicityCell Reports, 2021
- The role of type I interferon in the treatment of COVID‐19Journal of Medical Virology, 2021
- COVID-19 Vaccines vs Variants—Determining How Much Immunity Is EnoughJAMA, 2021
- Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19Cell, 2020
- Self-Assembly of Ferritin: Structure, Biological Function and Potential Applications in Nanotechnology2019
- Fc Receptors in Antimicrobial Protection2019
- Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected MiceCell Host & Microbe, 2016
- Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding SiteCell, 2015
- Evaluation of local MCP‐1 and IL‐12 nanocoatings for infection prevention in open fracturesJournal of Orthopaedic Research, 2009
- Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptorsArchives of Virology, 2009